Bausch Health Q3 revenue rises 10% to $2.94 billion; company raises 2026 guidance
Bausch Health reported third-quarter 2026 revenue of $2.94 billion, up 10% from the prior year, and GAAP diluted EPS of $1.15 versus $0.48. The company raised its full-year 2026 revenue and Adjusted EBITDA guidance and authorized a $50 million share repurchase program. The results and higher guidance point to improved profitability for shareholders, though the company's guidance notes ongoing tariff uncertainty.
Key points
- Q3 2026 consolidated revenue was $2.94 billion, up 10% (8% organic), versus $2.68 billion in Q3 2025
- GAAP diluted EPS was $1.15 versus $0.48; adjusted diluted EPS was $1.77 versus $1.16, an increase of 53%
- Full-year 2026 consolidated revenue guidance is $10.975 billion to $11.175 billion, and Adjusted EBITDA guidance is $4.315 billion to $4.415 billion
- Board authorized a $50 million share repurchase program, primarily to offset dilution from management equity awards expected to vest in 2027
The filing
Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 28, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.